Viridis Mining and Minerals (ASX:VMM) has reported new infill and exploration drilling results at its Colossus Project in Brazil, strengthening resource confidence and expanding the high-grade footprint within the Northern Concessions.

⛏️ Viridis’s infill drilling has delivered high-grade results exceeding expectations in rare earth deposits of TREO, with elevated Dysprosium and Terbium, strengthening confidence outlined in the Pre-Feasibility Study.
📈 Drilling has outperformed the existing block model, supporting expectations of a feed-grade uplift in the upcoming Mineral Resource Estimate update and adding to the potential for improved project economics.
🌍 Parallel greenfield exploration east of the Northern Concessions Brazil is targeting extensions to known mineralisation, with the aim of extending mine life and increasing development flexibility across the broader asset.

Viridis Mining and Minerals Managing Director, Rafael Moreno commented:
“The high-grade RC infill results from the Northern Concessions continue to confirm strong continuity, supporting conversion to Measured classification ahead of Final Investment Decision targeted for Q3 2026. This upgrade will underpin an updated Reserve and further strengthen project bankability as we complete the DFS and financing process in the coming months.”

Far East Gold (ASX:FEG) is advancing a quality portfolio of six copper and gold projects across Indonesia and Australia, underpinned by combined JORC resources of 1.54Moz gold and 190Mlb copper. During the quarter, the Company delivered high-grade drilling results at the Idenburg Project in Papua, expanded mineralised zones at Sua and North Bermol, progressed permitting milestones, and recommenced drilling at Mount Clark West in Queensland following a wet-season pause. Managing Director and CEO Shane Menere joins The Stock Network’s Lel Smits to discuss the latest drilling success, regulatory progress and how Far East Gold is positioning for sustained discovery-driven growth across its portfolio.

🇮🇩 High-grade growth at Idenburg – Sua and North Bermol, Indonesia
⚒️ Strong newsflow across multiple projects
🌏 Mount Clark West – copper upside in Queensland

If you’ve built wealth, have you really protected it? Building wealth is one challenge, protecting it is another entirely. Chubb’s latest Wealth Report highlights that as wealth becomes more complex, traditional protection approaches often fall short. Homes, businesses, and personal assets now face a wider range of risks, many of which aren’t fully addressed by standard policies or “set-and-forget” planning. Wealth protection today requires regular review, accurate valuations, and proactive risk management. It also requires understanding that not all losses are purely financial - emotional and lifestyle disruption can be just as significant. For HNWIs, true protection means aligning insurance, planning, and advice with how wealth is actually lived.

Contact Energy (ASX:CEN) has announced a $449 million equity raise to fast-track new battery, solar and geothermal projects as part of its Contact31+ renewable growth strategy, positioning the company as a leader in New Zealand’s energy transition.

🔋 Funds will support major developments including a new large-scale battery, a solar farm joint venture, and further geothermal expansion, strengthening New Zealand’s renewable energy supply.
🌿 The Company delivered a strong half-year result, driven by higher renewable generation and the successful acquisition and integration of Manawa Energy, with expected cost synergies already secured.
⚡ With renewable generation now making up nearly all of its output, Contact continues positioning itself as a leader in clean energy while investing to improve energy security and manage inconsistency risk.

Contact Energy CEO Mike Fuge commented:
“1H26 was transformational, with the completion of the Manawa acquisition and the welcoming of its people and assets to Contact. The strong performance of the combined entity set us up well for the year ahead as we take significant steps to execute the Contact31+ strategy.”

Forrestania Resources (ASX:FRS) has entered into a binding agreement to acquire 100% of MacPhersons Reward Pty Ltd, continuing its consolidation of the Coolgardie gold district in Western Australia.

🏗️ The acquisition includes granted and operating gold mining leases located within and adjacent to Forrestania’s existing Coolgardie Hub, strengthening its control over operations near processing infrastructure.
💰 The transaction will be funded through a mix of cash and shares, preserving capital while securing immediate mining tenure and supporting the Company’s transition from explorer to near-term gold producer.
⛏️ As mining at MacPhersons is nearing completion by Beacon Minerals, Forrestania can now fully integrate the site into its regional growth plans, expanding production and leveraging existing infrastructure, paving the road form exploration to production.

Forrestania Resources Executive Chairman David Geraghty commented:
“This acquisition continues Forrestania’s disciplined strategy of consolidating tenure around our Coolgardie Hub with specific focus on granted mining tenure. The MacPhersons tenements allow us to utilise nearby processing options and transition smoothly from explorer to producer.

Arovella Therapeutics (ASX:ALA) is a biotechnology company developing invariant natural killer T (iNKT) cell therapies for the treatment of blood cancers and solid tumours. In January 2026, Arovella achieved a major regulatory milestone with U.S. FDA acceptance of its investigational new drug (IND) for lead program ALA-101, validating its preclinical data, manufacturing process and clinical development plan and clearing the path for a first-in-human Phase 1 trial. The investigational new drug (IND) acceptance also establishes a regulatory framework for Arovella’s broader CAR-iNKT platform, supporting the advancement of additional programs including ALA-105 for gastric cancer and ahead of Wholesale Investor’s Emergence 2026 Conference, CEO and Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about the significance of this milestone and what comes next as Arovella enters the clinic.

🩺 Entering the clinic
⚕️ Building value beyond ALA-101

👉 Wholesale Investor`s Emergence 2026
🗓 18-20 February, 2026
📍 Four Seasons Hotel, Sydney

Percheron Therapeutics (ASX:PER) is an international biotechnology company developing novel therapies for oncology and rare diseases. During the December 2025 quarter, the Company reported final Phase I data for HMBD-002, confirming strong safety and encouraging efficacy signals, and outlined a modular Phase II clinical trial with manufacturing scheduled for the second quarter of this year and ahead of Wholesale Investor’s Emergence 2026 Conference, CEO and Managing Director Dr James Garner speaks with The Stock Network’s Lel Smits about clinical progress and the path into Phase II.

⚗️ Phase I results and clinical validation
🧪 Phase II strategy and near-term catalysts

👉 Wholesale Investor`s Emergence 2026
🗓 18-20 February, 2026
📍 Four Seasons Hotel, Sydney